Because many GLP-1 therapies are prescribed to individuals with obesity or metabolic syndrome, separating medication effects from underlying risk factors can be difficult
Users switching between medications should maintain their supplement protocol throughout the transition
However, while it is evident that DPP-4 has the potential to influence glycaemic control, its overall significance for the normal physiological regulation of glucose homeostasis in humans and its role in the pathogenesis of metabolic disease remain to be established
The American Diabetes Association's statement on compounded GLP-1 and dual GIP/GLP-1 receptor agonists warns that these unapproved products skip the FDA's review for safety, effectiveness, and quality
When we wait too long to eat, it is normal to get voraciously hungry
This publication has not received compensated product samples for testing, has not interviewed Trimi or Arora Health personnel, has not been granted access to internal product specifications beyond what is publicly published, and has not conducted independent laboratory or clinical testing of any compounded medication